Oxford Vacmedix
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Diagnostics
Oxford Vacmedix (OVM) is a clinical-stage University of Oxford biopharma spin-out with a proprietary recombinant overlapping peptides (ROP) technology platform for cancer (and viral) indications:
- Dual-mode of action by eliciting a cell-mediated response and a humoral response
- Intrinsic conversion of tumour-associated antigens into tumour-specific antigens for neoantigen-like efficacy and safety
FIH UK P1 trials of OVM-200 for ovarian cancer, prostate cancer and NSCLC have shown an excellent safety profile and very strong T-cell and strong, durable antibody responses. Preclinical studies of OVM-100 for HPV related cancers have shown complete responses with suppression of recurrence, in combination with IO agents.
Our vaccines are:
- Off-the-shelf
- HLA-type unrestricted
- Applicable to viral diseases and cancers
- Very quick to develop
- Inexpensive to manufacture with an e.coli process (OVM-200)
- Very stable - 4 years+ (OVM-200)
- Easy to store – no ultra-low temperature storage
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}